However, previous studies found that the dysregulation of UCN2/CRFR2 signaling was associated with prostate cancer [49], non-small cell lung carcinoma [50], colorectal cancer (CRC) [21], Lewis lung carcinoma (LLC) [47], and human adrenal and ovarian tumors [51]. This evidence concerns the gene CRHR2 and colorectal cancer.